Your immune system is supposed to protect you. It fights off infections, neutralizes threats and keeps your body running the way it should. So what happens when that same system turns against your own skin?
That’s the central question behind immunodermatology, a subspecialty of dermatology focused on how immune dysfunction drives chronic skin conditions like psoriasis, vitiligo, atopic dermatitis (eczema) and lichen planus. These are conditions where the immune system misfires, creating inflammation, tissue damage or pigment loss in the skin. And they’re far more common than most people realize.
At AboutSkin Dermatology and Aesthetics in Denver, our Board-Certified Dermatologists treat immune-mediated skin diseases with the same research-driven precision that has earned the practice recognition as one of the World’s Leading Clinics and Dr. Joel Cohen the distinction of being a 15-time Castle Connolly Top Doctor. With over 100 clinical research studies conducted since 2004, the team stays at the forefront of how science is reshaping treatment for these complex conditions.
What Is Immunodermatology?
Immunodermatology is the study of skin diseases caused by abnormal immune responses. The immune system is the body’s defense network, made up of cells, proteins and signaling molecules designed to identify and destroy foreign invaders like viruses and bacteria. In autoimmune and immune-mediated skin conditions, that defense system malfunctions and begins attacking healthy tissue instead.
The result can look very different depending on the condition. Psoriasis causes rapid skin cell turnover and thick, scaly plaques. Vitiligo destroys the melanocytes responsible for skin pigment. Atopic dermatitis triggers persistent itching and inflamed skin from a disrupted skin barrier and overactive immune signaling. What these conditions share is a common root: the immune system doing damage rather than defense.
Dr. Brooke Rothstein, a Board-Certified Dermatologist at AboutSkin Dermatology and Aesthetics, dedicated a full year of her medical training to clinical trial research focused on psoriasis, vitiligo and atopic dermatitis. This experience has helped inform her approach to diagnosing and managing these conditions today.
Psoriasis: When Skin Cell Production Goes Into Overdrive
Psoriasis is one of the most well-studied immune-mediated skin diseases in the world. According to a 2021 study published in JAMA Dermatology, the prevalence of psoriasis among adults in the U.S. is approximately 3%, affecting more than 7.5 million people age 20 and older.
In psoriasis, overactive T cells (a type of white blood cell) trigger an inflammatory cascade that speeds up skin cell production. Normal skin cells take about one month to mature and shed. In psoriatic skin, that cycle compresses to just three to four days, causing cells to pile up on the surface and form the characteristic red, raised plaques covered in silvery scales.
The key immune players in psoriasis include T helper 17 (Th17) cells and a group of signaling proteins called interleukins, particularly IL-17 and IL-23. These molecules amplify the inflammatory response and keep the cycle going. Understanding this mechanism has led to a wave of targeted treatments that work from the inside out.
“Psoriasis is a systemic disease, not just a skin problem,” says Dr. Cohen, who has authored over 324 medical articles and book chapters throughout his career. “When we treat psoriasis effectively, we’re addressing inflammation that can affect the joints, the cardiovascular system and overall quality of life.”
Vitiligo: The Immune System vs. Your Pigment Cells
Vitiligo develops when the immune system destroys melanocytes, the cells that produce melanin and give the skin its color. The result is white, depigmented patches that can appear anywhere on the body. Researchers believe a combination of genetic predisposition and environmental triggers (such as stress, sunburn or chemical exposure) can set off the autoimmune response.
At a cellular level, cytotoxic CD8+ T cells are the primary aggressors in vitiligo. These cells target and kill melanocytes, and the inflammatory signals they release (including interferon-gamma and the CXCL10 chemokine) recruit more immune cells to the area, worsening pigment loss over time.
Vitiligo affects an estimated 1% to 2% of the global population. While it can develop at any age, most people notice the first patches before age 30.
Atopic Dermatitis: A Barrier Problem Meets an Immune Problem
Atopic dermatitis (commonly known as eczema) is the most common inflammatory skin condition, and it often begins in childhood. It involves a two-part problem: a weakened skin barrier that lets irritants and allergens penetrate more easily, and an overactive immune response that generates chronic inflammation in reaction to those triggers.
The immune pathway in atopic dermatitis is dominated by Th2 cells, which release interleukins IL-4 and IL-13. These cytokines drive the itching, redness and skin barrier dysfunction that define the condition. In more severe or chronic cases, other immune pathways (including Th1 and Th22) can also become involved, making the disease harder to control with topical treatments alone.
For patients with moderate to severe atopic dermatitis who haven’t responded well to topical therapies, the AboutSkin medical dermatology team offers biologics (injectable and oral systemic medications) that target these specific immune pathways rather than suppressing the entire immune system.
Lichen Planus and Other Immune-Driven Conditions
The list of skin conditions linked to immune dysfunction extends well beyond psoriasis, vitiligo and eczema. Lichen planus is an inflammatory condition believed to be autoimmune in origin, where the body’s immune cells attack the skin, mucous membranes and sometimes the hair and nails. It produces purple, flat-topped, intensely itchy bumps on the skin and can cause painful sores in the mouth.
Alopecia areata, another autoimmune condition, occurs when immune cells attack hair follicles, causing patchy or widespread hair loss. And cutaneous T-cell lymphoma is a rare cancer of the immune system that originates in the skin’s own T cells and can initially mimic eczema or psoriasis, making early diagnosis critical.
How Modern Therapies Target the Immune System
The treatment landscape for immune-mediated skin diseases has changed dramatically over the past two decades. Where doctors once relied almost exclusively on broad immunosuppressants and topical steroids, today’s therapies can zero in on specific molecules and immune pathways driving a particular condition.
- Biologics are injectable or oral medications engineered to block specific immune proteins. In psoriasis treatment, biologics that target TNF-alpha, IL-17 or IL-23 have shown the ability to clear skin significantly. For atopic dermatitis, biologics targeting IL-4 and IL-13 have opened new options for patients who struggled with older treatments.
- Topical and phototherapy options remain useful for milder presentations. Topical calcineurin inhibitors, corticosteroids and narrowband UVB light therapy continue to play a role in managing localized disease, often alongside systemic treatments for more widespread involvement.
- JAK inhibitors are a newer class of oral medications gaining traction across dermatology. These drugs block Janus kinase enzymes involved in immune signaling and have gained FDA approval for conditions including atopic dermatitis and alopecia areata. Research into their use for vitiligo is also expanding rapidly.
At AboutSkin Dermatology and Aesthetics, our physicians evaluate the skin condition while looking at the whole clinical picture; they consider severity, how the disease affects daily life, and whether related health concerns like psoriatic arthritis or cardiovascular risk factors need attention.
Why a Board-Certified Dermatologist Matters for Immune-Mediated Skin Conditions
Immune-mediated skin diseases are complex. They can look similar on the surface but require very different treatment strategies depending on the underlying immune pathway involved. A Board-Certified Dermatologist with experience in these conditions can distinguish between overlapping presentations, order the appropriate workup and select targeted therapies that address the root cause rather than just managing symptoms.
Dr. Cohen, who is also an Associate Professor of Dermatology at the University of California, Irvine, and has been quoted in publications including Vogue, TIME magazine and The New York Times, brings a perspective shaped by decades of clinical research and global collaboration. That research-informed approach is woven into how the entire team at AboutSkin evaluates and manages chronic skin conditions for patients across the Denver metro area.
Your Immune System Has Met Its Match
If you’re dealing with a persistent skin condition that doesn’t respond to over-the-counter treatments, the answer may lie deeper than the surface. The Board-Certified Dermatologists at AboutSkin Dermatology and Aesthetics in Greenwood Village are here to help you understand what’s driving your skin concerns and find the right treatment approach. Call 303-756-7546 or contact our team online to schedule your consultation.
